Search Results 41-50 of 22856 for Lateral

  1. A Study to Evaluate MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    A Study to Evaluate MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients with Amyotrophic Lateral Sclerosis (ALS).

  2. A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers - Mayo Clinic

    The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to ...

  3. TJ-68 Clinical Trial in Patients with Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps

    The purpose of this study is to demonstrate the safety and potential effectiveness of TJ-68 for improving muscle cramps in participants with Amyotrophic Lateral ...

  4. Bilateral Lateral Rectus Recession Versus Unilateral Recess-Resect for Intermittent Exotropia - Mayo Clinic

    About this study. The purpose of this study is to evaluate the effectiveness of bilateral lateral rectus muscle recession versus unilateral lateral rectus ...

  5. Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) · More about research at Mayo Clinic · Mayo Clinic Footer.

  6. Diaphragm Pacing System (DPS) in Participants with Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    Diaphragm Pacing System (DPS) in Participants with Amyotrophic Lateral Sclerosis (ALS) · Overview · Participation eligibility · Participating Mayo Clinic locations.

  7. Meralgia paresthetica - Diagnosis and treatment - Mayo Clinic

    Pain relief achieved from anesthetic injection into your thigh where the lateral femoral cutaneous nerve enters into it can confirm that you have meralgia ...

  8. Experimental Antisense Oligonucleotide Treatment for Amyotrophic Lateral Sclerosis With an arg15leu Pathogenic Variant in CHCHD10. - Mayo Clinic

    Experimental Antisense Oligonucleotide Treatment for Amyotrophic Lateral Sclerosis With an arg15leu Pathogenic Variant in CHCHD10. · Overview · Participation ...

  9. Pridopidine in Amyotrophic Lateral Sclerosis (EAP 2) - Mayo Clinic

    The purpose of this study is to provide access to the investigational product, pridopidine, for up to 200 participants with ALS who are ineligible for clinical ...

  10. Doctors and departments - Mayo Clinic

    Amyotrophic lateral sclerosis (ALS). Departments and specialties. Mayo Clinic has one of the largest and most experienced practices in the United States, with ...